Amneal Pharmaceuticals downgraded by StockNews.com from strong-buy to buy rating.
Amneal Pharmaceuticals (AMRX) downgraded by StockNews.com from a strong-buy to a buy rating. Other analysts have recently upgraded the stock: Barclays increased price objective from $6.00 to $8.00 (overweight), The Goldman Sachs Group raised from $5.50 to $6.25 (buy), and Truist Financial boosted from $6.00 to $7.00 (buy). Five analysts have given a buy rating, with a consensus rating of Buy and a consensus price target of $6.56.
March 07, 2024
3 Articles